Visit other SMART + STRONG sites:
POZREAL HEALTHTU SALUD
Subscribe to:
E-newsletters
POZ magazine
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Life Expectancy With HIV Increases Dramatically
HIV Eradication: One Step Closer
Scientists Crack Integrase Inhibitor Mystery
Gilead Reports Success With Quad Pill and Boosting Drug
New Hope for HIV Eradication
Study: Demand for HIV Vaccine Will Depend on How Good It Is
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailrssprint

January 4, 2008

Potential Drug Interaction Between Sustiva and Dilantin

The anticonvulsant Dilantin (phenytoin) can drastically reduce levels of the HIV drug efavirenz—found in Sustiva/Stocrin and Atripla—in the blood when both medications are used together, according to an article published by AIDSmap reviewing a case report in the January 2 issue of AIDS.

Cedric Spak, MD, from the University of Washington, Harborview Medical Center-Madison Clinic in Seattle, and his colleagues describe treating a man with a history of epilepsy who was diagnosed with HIV after presenting with oral thrush and wasting syndrome. The patient, who’d been taking Dilantin to manage his seizures, was first given Diflucan (fluconazole) to treat his thrush and other medications to prevent MAC and PCP. Because Diflucan can interact with Dilantin, his Dilantin dose was reduced. Once his thrush improved and his weight increased, Spak’s team decided to initiate antiretroviral therapy with a regimen containing Sustiva.

Though it was suspected that Dilantin could potentially reduce Sustiva blood levels, Spak’s team was more concerned about the Rifadin (rifampin)—an antibiotic that can reduce Sustiva levels by up to 30 percent—which he was receiving to prevent MAC. In turn, the team prescribed an 800 mg once-daily dose of Sustiva—200 mg higher than the standard dose.

Blood levels of Sustiva were monitored, and on the fourth and the 14th day of treatment were found to be undetectable. Despite this, however, the patient’s viral load had fallen from a high of over 1 million copies to just 12,400 copies, likely due to the Truvada (tenofovir and emtricitabine) he was taking in combination with Sustiva. After learning of the day 14 results, Spak’s team switched the patient from Dilantin to another anticonsulsive drug, and further increased the Sustiva dose to 600 mg twice a day. Two weeks later, the amount of Sustiva in the patient’s blood had approached normal levels and his viral load had fallen further to 921 copies. At this point, the team lowered the patient’s dose of Sustiva to the standard 600 mg once daily.

While the discontinuation of Dilantin resulted in a return of Sustiva blood levels toward normal, it is possible that the patient’s concurrent use of Rifadin made any potential interaction worse. Also, Spak’s team is quick to point out that because blood levels of Sustiva can vary a great deal among different people, the results seen in this patient cannot be generalized. News of this interaction, however, should advise doctors to proceed with caution when treating patients who are HIV positive and have seizure disorders.


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

comments 1 - 2 (of 2 total)    

David Evans, AIDSmeds, New York, AIDSmeds.com, 2008-01-11 17:58:58
Dear Jane, First, you should always tell your doctor about any problems you may be having. Also, efavirenz can interact with TB medication - make sure to discuss this with your doctor

jane wanjiku, Nairobi, 2008-01-10 04:25:55
I started arvs on 1st of this and i have been on TB drugs for four months. The pain on the sides is coming back just like it was before i knew it was TB. Should i get worried or it's the effect of arv's. Am currently on efavirenz and coviro

comments 1 - 2 (of 2 total)    


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
My Cool Tools
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine
Conference Coverage

17th Conference on Retroviruses and Opportunistic Infections (CROI 2010)
San Francisco, CA
February 16-19, 2010


5th IAS Conference on HIV Pathogenesis Treatment and Prevention (IAS 2009)
Cape Town, South Africa
July 19-22, 2009


16th Conference on Retroviruses and Opportunistic Infections (CROI 2009)
Montréal, Canada
February 8-11, 2009

more conference coverage


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2010 Smart + Strong. All Rights Reserved. Terms of use and Your privacy